Search
for
Sort by
Research 31–60 of 388
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Ritlecitinib: First Approval
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Janus kinase inhibitors for alopecia areata: A narrative review
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- DKK1 Mediated Inhibition of Wnt Signaling in Postnatal Mice Leads to Loss of TEC Progenitors and Thymic Degeneration
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Hair Follicle Reconstruction and Stem Cells